Non-VKA oral anticoagulants: Accurate measurement of plasma drug concentrations

Research output: Contribution to journalReview article

Abstract

Non-VKA oral anticoagulants (NOACs) have now widely reached the lucrative market of anticoagulation. While the marketing authorization holders claimed that no routine monitoring is required and that these compounds can be given at fixed doses, several evidences arisen from the literature tend to demonstrate the opposite. New data suggests that an assessment of the response at the individual level could improve the benefit-risk ratio of at least dabigatran. Information regarding the association of rivaroxaban and apixaban exposure and the bleeding risk is available in the drug approval package on the FDA website. These reviews suggest that accumulation of these compounds increases the risk of experiencing a bleeding complication. Therefore, in certain patient populations such as patients with acute or chronic renal impairment or with multiple drug interactions, measurement of drug exposure may be useful to ensure an optimal treatment response. More specific circumstances such as patients experiencing a haemorrhagic or thromboembolic event during the treatment duration, patients who require urgent surgery or an invasive procedure, or patient with a suspected overdose could benefit from such a measurement. This paper aims at providing guidance on how to best estimate the intensity of anticoagulation using laboratory assays in daily practice.

Original languageEnglish
Article number345138
JournalBioMed research international
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

Anticoagulants
Plasmas
Drug interactions
Pharmaceutical Preparations
Surgery
Websites
Marketing
Assays
Hemorrhage
Drug Approval
Association reactions
Drug Interactions
Monitoring
Odds Ratio
Kidney
Therapeutics
Population
apixaban
Rivaroxaban
Dabigatran

Cite this

@article{7a1ea8527a864a9392f3053e3bcea4cd,
title = "Non-VKA oral anticoagulants: Accurate measurement of plasma drug concentrations",
abstract = "Non-VKA oral anticoagulants (NOACs) have now widely reached the lucrative market of anticoagulation. While the marketing authorization holders claimed that no routine monitoring is required and that these compounds can be given at fixed doses, several evidences arisen from the literature tend to demonstrate the opposite. New data suggests that an assessment of the response at the individual level could improve the benefit-risk ratio of at least dabigatran. Information regarding the association of rivaroxaban and apixaban exposure and the bleeding risk is available in the drug approval package on the FDA website. These reviews suggest that accumulation of these compounds increases the risk of experiencing a bleeding complication. Therefore, in certain patient populations such as patients with acute or chronic renal impairment or with multiple drug interactions, measurement of drug exposure may be useful to ensure an optimal treatment response. More specific circumstances such as patients experiencing a haemorrhagic or thromboembolic event during the treatment duration, patients who require urgent surgery or an invasive procedure, or patient with a suspected overdose could benefit from such a measurement. This paper aims at providing guidance on how to best estimate the intensity of anticoagulation using laboratory assays in daily practice.",
author = "Jonathan Douxfils and Helen Mani and Valentine Minet and B{\'e}rang{\`e}re Devalet and Bernard Chatelain and Dogn{\'e}, {Jean Michel} and Fran{\cc}ois Mullier",
year = "2015",
doi = "10.1155/2015/345138",
language = "English",
volume = "2015",
journal = "BioMed research international",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Non-VKA oral anticoagulants: Accurate measurement of plasma drug concentrations

AU - Douxfils, Jonathan

AU - Mani, Helen

AU - Minet, Valentine

AU - Devalet, Bérangère

AU - Chatelain, Bernard

AU - Dogné, Jean Michel

AU - Mullier, François

PY - 2015

Y1 - 2015

N2 - Non-VKA oral anticoagulants (NOACs) have now widely reached the lucrative market of anticoagulation. While the marketing authorization holders claimed that no routine monitoring is required and that these compounds can be given at fixed doses, several evidences arisen from the literature tend to demonstrate the opposite. New data suggests that an assessment of the response at the individual level could improve the benefit-risk ratio of at least dabigatran. Information regarding the association of rivaroxaban and apixaban exposure and the bleeding risk is available in the drug approval package on the FDA website. These reviews suggest that accumulation of these compounds increases the risk of experiencing a bleeding complication. Therefore, in certain patient populations such as patients with acute or chronic renal impairment or with multiple drug interactions, measurement of drug exposure may be useful to ensure an optimal treatment response. More specific circumstances such as patients experiencing a haemorrhagic or thromboembolic event during the treatment duration, patients who require urgent surgery or an invasive procedure, or patient with a suspected overdose could benefit from such a measurement. This paper aims at providing guidance on how to best estimate the intensity of anticoagulation using laboratory assays in daily practice.

AB - Non-VKA oral anticoagulants (NOACs) have now widely reached the lucrative market of anticoagulation. While the marketing authorization holders claimed that no routine monitoring is required and that these compounds can be given at fixed doses, several evidences arisen from the literature tend to demonstrate the opposite. New data suggests that an assessment of the response at the individual level could improve the benefit-risk ratio of at least dabigatran. Information regarding the association of rivaroxaban and apixaban exposure and the bleeding risk is available in the drug approval package on the FDA website. These reviews suggest that accumulation of these compounds increases the risk of experiencing a bleeding complication. Therefore, in certain patient populations such as patients with acute or chronic renal impairment or with multiple drug interactions, measurement of drug exposure may be useful to ensure an optimal treatment response. More specific circumstances such as patients experiencing a haemorrhagic or thromboembolic event during the treatment duration, patients who require urgent surgery or an invasive procedure, or patient with a suspected overdose could benefit from such a measurement. This paper aims at providing guidance on how to best estimate the intensity of anticoagulation using laboratory assays in daily practice.

UR - http://www.scopus.com/inward/record.url?scp=84930958955&partnerID=8YFLogxK

U2 - 10.1155/2015/345138

DO - 10.1155/2015/345138

M3 - Review article

VL - 2015

JO - BioMed research international

JF - BioMed research international

SN - 2314-6133

M1 - 345138

ER -